Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01116427 · ClinicalTrials.gov registry record · Phase 2
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT01116427 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 65 participants.
The verdict
NCT01116427, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The ACCLAIM study is testing whether the medication "abatacept" can be of benefit to patients with relapsing-remitting multiple sclerosis (MS). Although abatacept is an investigational medication for MS, it is not a new drug. Abatacept has been approved by the FDA to treat rheumatoid arthritis.
Interventions
- DRUG Placebo
- BIOLOGICAL abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2010-09 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01116427
The ClinicalTrials.gov registry entry for NCT01116427 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01116427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01116427 about?
NCT01116427 is a clinical study titled "A Cooperative Clinical Study of Abatacept in Multiple Sclerosis". The ACCLAIM study is testing whether the medication "abatacept" can be of benefit to patients with relapsing-remitting multiple sclerosis (MS). Although abatacept is an investigational medication for MS, it is not a new drug. Abatacept has been approved by the FDA to treat rheumatoid arthritis.
What is the current status of trial NCT01116427?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2010-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01116427?
The interventions under investigation include: Placebo (DRUG), abatacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT01116427?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.